The Insider Activity Of Sarepta Therapeutics Inc. (SRPT) Should Not Be Ignored

As of Friday close, Sarepta Therapeutics Inc.’s (NASDAQ:SRPT) stock was up $4.57, moving up 4.50 percent to $106.02. The average number of shares traded per day over the past five days has been 1,474,220 shares. 5 times new highs have been achieved over the past 5 days, with a $13.07 gain in that time frame. In the last twenty days, the average volume was 1,006,275, while in the previous 50 days, it was 897,516.

Since last month, SRPT stock rose 33.02%. Shares of the company fell to $72.02 on 07/06/22, the lowest level in the past month. A 52-week high of $103.16 was reached on 08/05/22 after having rallying from a 52-week low of $61.28. Since the beginning of this year, SRPT’s stock price has risen by 17.73% or $15.97, and marked a new high 6 times. However, the stock has increased by 2.77% since its 52-week high.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Sarepta Therapeutics Inc. (SRPT) last reported insider trading activity 255 days ago on Nov 24. Rodino-Klapac Louise, the Head of R&D, CSO of the company, purchased of 3,780 shares for $79.33 on Nov 24. It resulted in a $299,867 investment by the insider. INGRAM DOUGLAS S added 25,026 shares at an average price of $79.94 on Nov 17. The insider now owns 365,082 shares following the transaction.

Valuation Metrics

The stock’s beta is 1.22. Besides these, the trailing price-to-sales (P/S) ratio of 11.19, the price-to-book (PB) ratio of 10.80.

Financial Health

In the three months ended March 30, Sarepta Therapeutics Inc.’s quick ratio stood at 5.10, while its current ratio was 5.60, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 1.28, and the total debt-to-equity ratio was 1.28. On the profitability front, the trailing twelve-month gross margin is 86.10% percent. In the year ended March 30, operating margins totaled -38.80%. Based on annual data, SRPT earned $604.84 million in gross profit and brought in $701.89 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -17.90%. Return on equity (ROE) for the past 12 months was -52.10%.

In Sarepta Therapeutics Inc.’s quarter-end financial report for March 30, it reported total debt of $1.1 billion against cash and short-term investments of $1.06 billion. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. SRPT’s revenue rose 29.72% to $210.83 million during the quarter, while net income inched up to $233.49 million. While analysts expected Sarepta Therapeutics Inc. to report -$1.27 quarterly earnings, the actual figure was -$1.2 per share, beating the consensus estimate by 5.50%. During the quarter, the company generated -$201.24 million in EBITDA. The liabilities of Sarepta Therapeutics Inc. were 2.27 billion at the end of its most recent quarter ended March 30, and its total debt was $1.16 billion. The value of shareholders’ equity is $87.57 million.

Technical Picture

This quick technical analysis looks at Sarepta Therapeutics Inc.’s (SRPT) price momentum. With a historical volatility rate of 42.77%, the RSI 9-day stood at 89.53% on 05 August.

With respect to its five-day moving average, the current Sarepta Therapeutics Inc. price is up by +14.06% percent or $13.07. At present, SRPT shares trade +31.75% above its 20-day simple moving average and +42.23% percent above its 100-day simple moving average. However, the stock is currently trading approximately +54.01% above its SMA50 and +31.80% above its SMA200.

Stochastic coefficient K was 95.82% and Stochastic coefficient D was 92.02%, while ATR was 4.42. Given the Stochastic reading of 96.08% for the 14-day period, the RSI (14) reading has been calculated as 84.83%. As of today, the MACD Oscillator reading stands at 8.26, while the 14-day reading stands at 11.31.

Analyst Ratings

Sarepta Therapeutics Inc. (SRPT) has been rated Overweight by analysts. According to 0 brokerage firms, SRPT is a sell, and 5 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 2 analysts rate Sarepta Therapeutics Inc. stock as buy, with 14 recommending it as overweight.

With a median target price of $123.50, the current consensus forecast for the stock is $93.00 – $162.00. Based on these forecasts, analysts predict Sarepta Therapeutics Inc. (SRPT) will achieve an average price target of $124.25.


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles